Below, we focused on TCR-T cells, which mainly target cancer testis antigens, including NY-ESO-1, MAGE-A3, MAGE-A4, and systematically reviewed the relevant preclinical and clinical studies of TCR-T therapy against esophageal cancer. This evidence concerns the gene MAGEA4 and esophageal cancer.